{
    "paper_id": "51c91ed9dc04745b46f7575671bbb361bbb09bf7",
    "metadata": {
        "title": "Title: Potent programmable antiviral against dengue virus in primary human 1 cells by Cas13b RNP with short spacer and delivery by virus-like particle. 2 3",
        "authors": [
            {
                "first": "Ekapot",
                "middle": [],
                "last": "Singsuksawat",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Klong Luang",
                    "location": {
                        "addrLine": "10",
                        "postCode": "12120 11",
                        "settlement": "Pathumthani"
                    }
                },
                "email": ""
            },
            {
                "first": "Suppachoke",
                "middle": [],
                "last": "Onnome",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Klong Luang",
                    "location": {
                        "addrLine": "10",
                        "postCode": "12120 11",
                        "settlement": "Pathumthani"
                    }
                },
                "email": ""
            },
            {
                "first": "Posiri",
                "middle": [],
                "last": "",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Amporn",
                "middle": [],
                "last": "Suphatrakul",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Klong Luang",
                    "location": {
                        "addrLine": "10",
                        "postCode": "12120 11",
                        "settlement": "Pathumthani"
                    }
                },
                "email": ""
            },
            {
                "first": "Nittaya",
                "middle": [],
                "last": "Srisuk",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Klong Luang",
                    "location": {
                        "addrLine": "10",
                        "postCode": "12120 11",
                        "settlement": "Pathumthani"
                    }
                },
                "email": ""
            },
            {
                "first": "Rapirat",
                "middle": [],
                "last": "Nantachokchawapan",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Klong Luang",
                    "location": {
                        "addrLine": "10",
                        "postCode": "12120 11",
                        "settlement": "Pathumthani"
                    }
                },
                "email": ""
            },
            {
                "first": "Hansa",
                "middle": [],
                "last": "Praneechit",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Klong Luang",
                    "location": {
                        "addrLine": "10",
                        "postCode": "12120 11",
                        "settlement": "Pathumthani"
                    }
                },
                "email": ""
            },
            {
                "first": "Chutimon",
                "middle": [],
                "last": "Sae-Kow",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Klong Luang",
                    "location": {
                        "addrLine": "10",
                        "postCode": "12120 11",
                        "settlement": "Pathumthani"
                    }
                },
                "email": ""
            },
            {
                "first": "Pala",
                "middle": [],
                "last": "Chidpratum",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Klong Luang",
                    "location": {
                        "addrLine": "10",
                        "postCode": "12120 11",
                        "settlement": "Pathumthani"
                    }
                },
                "email": ""
            },
            {
                "first": "Suradej",
                "middle": [],
                "last": "Hongeng",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Mahidol 14 University",
                    "location": {
                        "postCode": "10400",
                        "settlement": "Bangkok"
                    }
                },
                "email": ""
            },
            {
                "first": "Panisadee",
                "middle": [],
                "last": "Avirutnan",
                "suffix": "",
                "affiliation": {
                    "laboratory": "Dengue Research Unit",
                    "institution": "Mahidol University",
                    "location": {
                        "addrLine": "12",
                        "postCode": "10700 13",
                        "settlement": "Bangkok"
                    }
                },
                "email": ""
            },
            {
                "first": "Thaneeya",
                "middle": [],
                "last": "Duangjinda",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Klong Luang",
                    "location": {
                        "addrLine": "10",
                        "postCode": "12120 11",
                        "settlement": "Pathumthani"
                    }
                },
                "email": ""
            },
            {
                "first": "Bunpote",
                "middle": [],
                "last": "Siridechadilok",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Klong Luang",
                    "location": {
                        "addrLine": "10",
                        "postCode": "12120 11",
                        "settlement": "Pathumthani"
                    }
                },
                "email": ""
            }
        ]
    },
    "abstract": [],
    "body_text": [
        {
            "text": "With sequencing as a standard frontline protocol to identify emerging viruses such 25 zika virus and SARS-CoV2, direct utilization of sequence data to program antivirals 26 against the viruses could accelerate drug development to treat their infections. 27 CRISPR-Cas effectors are promising candidates that could be programmed to 28 inactivate viral genetic material based on sequence data but several challenges such 29 as delivery and design of effective crRNA need to be addressed to realize practical 30 use. Here, we showed that virus-like particle (VLP) could deliver PspCas13b-crRNA To characterize the antiviral activity of CRISPR-Cas13 against flavivirus, we first 61 established a stable BHK21 clone (BHK21-Cas13b) that could be induced with 62 doxycycline to express PspCas13b using lentivirus (Supplementary Figure 1a) . 63",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 806,
                    "end": 831,
                    "text": "(Supplementary Figure 1a)",
                    "ref_id": null
                }
            ],
            "section": ""
        },
        {
            "text": "Type I-interferon defective BHK21 cell line was chosen as the host cell for its ability 64 to support high level of dengue virus (DENV) and zika virus (ZIKV) replication (Liu et 65 al., 2006) , providing a robust platform to evaluate viral suppression activity. 66",
            "cite_spans": [
                {
                    "start": 170,
                    "end": 191,
                    "text": "(Liu et 65 al., 2006)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Inducible expression system appeared to provide the stability of Cas13b cassette in 67 BHK21 as we were not able to maintain PspCas13b expression under a constitutive for subsequent experiments (Supplementary Figure 1b) . Though Figure 1b) . The suppression of DENV2-mCherry by mCh3 crRNA 80 was specific as other reporter DENV2 could not be suppressed by the crRNA in both 81 single-virus infection and co-infection settings (Supplementary Figures 1c-d) . 82",
            "cite_spans": [
                {
                    "start": 222,
                    "end": 228,
                    "text": "Though",
                    "ref_id": null
                }
            ],
            "ref_spans": [
                {
                    "start": 194,
                    "end": 219,
                    "text": "(Supplementary Figure 1b)",
                    "ref_id": null
                },
                {
                    "start": 229,
                    "end": 239,
                    "text": "Figure 1b)",
                    "ref_id": null
                },
                {
                    "start": 426,
                    "end": 454,
                    "text": "(Supplementary Figures 1c-d)",
                    "ref_id": null
                }
            ],
            "section": ""
        },
        {
            "text": "Using BHK21-Cas13b, we individually tested 51 crRNAs against the targets on 83 DENV2 reporter viruses, DENV2-16681 (NS5 gene), and ZIKV-SV0010 (NS2A 84 gene) (Supplementary Table 1 (Pewkliang et al., 2018) ). The 118",
            "cite_spans": [
                {
                    "start": 181,
                    "end": 205,
                    "text": "(Pewkliang et al., 2018)",
                    "ref_id": null
                }
            ],
            "ref_spans": [
                {
                    "start": 173,
                    "end": 180,
                    "text": "Table 1",
                    "ref_id": null
                }
            ],
            "section": ""
        },
        {
            "text": "VLP was effective at delivering YFP to these cells (Supplementary Figure 1b) . We 119 found that the VSV-G pseudotyped VLP preferentially target CD14 + monocytes in 120 (Supplementary Figures 3a-b) . Nevertheless, the 142 knock-down activity of two crRNAs (mAmet1 and 8681) were aggravated by 22-nt 143 spacer (Supplementary Figures 3a-b) . We selected three pairs of 30-nt vs. 22-nt crRNAs for testing by VLP delivery in BHK21 cells. The knock-down enhancement 145 was recapitulated with Cas13b RNP delivery by VLP for 22-nt vs. 30-nt mCh3 146 crRNAs (Figure 3c) . In contrast to the results in BHK21-Cas13b, the 22-nt mAmet-1 147 crRNA could knock down DENV2-mAmet with much less PspCas13b than its 30-nt 148 counterpart (Figure 3c) . The dose-response curves indicated that the 22-nt mCh3 149 and mAmet1 crRNAs needed 15-20 folds less of PspCas13b than 30-nt crRNAs to 150 achieve the same level of virus suppression (Figure 2c) The isolated CD14 + monocytes were cultured in R10 supplemented with 5% HI-316 human AB serum to allow differentiation into macrophages (Brugger et al., 1991) . crRNA array with three crRNAs, 2x = crRNA array with two crRNAs, 1x = singlet",
            "cite_spans": [
                {
                    "start": 1068,
                    "end": 1090,
                    "text": "(Brugger et al., 1991)",
                    "ref_id": "BIBREF1"
                }
            ],
            "ref_spans": [
                {
                    "start": 51,
                    "end": 76,
                    "text": "(Supplementary Figure 1b)",
                    "ref_id": null
                },
                {
                    "start": 169,
                    "end": 197,
                    "text": "(Supplementary Figures 3a-b)",
                    "ref_id": "FIGREF8"
                },
                {
                    "start": 310,
                    "end": 338,
                    "text": "(Supplementary Figures 3a-b)",
                    "ref_id": "FIGREF8"
                },
                {
                    "start": 552,
                    "end": 563,
                    "text": "(Figure 3c)",
                    "ref_id": "FIGREF8"
                },
                {
                    "start": 723,
                    "end": 734,
                    "text": "(Figure 3c)",
                    "ref_id": "FIGREF8"
                },
                {
                    "start": 920,
                    "end": 931,
                    "text": "(Figure 2c)",
                    "ref_id": null
                }
            ],
            "section": ""
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "of dengue virus infection",
            "authors": [],
            "year": null,
            "venue": "Journal of Virology",
            "volume": "85",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1128/JVI.00220-10"
                ]
            }
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Macrophage colony-stimulating factor 585 is required for human monocyte survival and acts as a cofactor for their terminal 586 differentiation to macrophages in vitro",
            "authors": [
                {
                    "first": "W",
                    "middle": [],
                    "last": "Brugger",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Kreutz",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Andreesen",
                    "suffix": ""
                }
            ],
            "year": 1991,
            "venue": "J. Leukoc. Biol",
            "volume": "49",
            "issn": "",
            "pages": "483--488",
            "other_ids": {
                "DOI": [
                    "10.1002/jlb.49.5.483"
                ]
            }
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Detection of Zika Virus Infection in Thailand",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Akrasewi",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Plipat",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Am. J. Trop. Med. Hyg",
            "volume": "93",
            "issn": "",
            "pages": "380--383",
            "other_ids": {
                "DOI": [
                    "10.4269/ajtmh.15-0022"
                ]
            }
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "A versatile viral 594 system for expression and depletion of proteins in mammalian cells",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Campisi",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Yaswen",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "K"
                    ],
                    "last": "Cooper",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "D"
                    ],
                    "last": "Kaufman",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "PLoS ONE",
            "volume": "595",
            "issn": "4",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1371/journal.pone.0006529"
                ]
            }
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "RNA editing with CRISPR-Cas13",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Science",
            "volume": "550",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1126/science.aaq0180"
                ]
            }
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "Phenotyping of peripheral blood mononuclear 601 cells during acute dengue illness demonstrates infection and increased activation 602 of monocytes in severe cases compared to classic dengue fever",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Balmaseda",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Harris",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Virology",
            "volume": "376",
            "issn": "",
            "pages": "603--429",
            "other_ids": {
                "DOI": [
                    "10.1016/j.virol.2008.03.028"
                ]
            }
        },
        "BIBREF13": {
            "ref_id": "b13",
            "title": "Programmable Inhibition and Detection of RNA Viruses Using",
            "authors": [
                {
                    "first": "P",
                    "middle": [
                        "C"
                    ],
                    "last": "Sabeti",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF15": {
            "ref_id": "b15",
            "title": "Multiplexed and portable nucleic acid detection platform with Cas13",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "S"
                    ],
                    "last": "Gootenberg",
                    "suffix": ""
                },
                {
                    "first": "O",
                    "middle": [
                        "O"
                    ],
                    "last": "Abudayyeh",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "J"
                    ],
                    "last": "Kellner",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Joung",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "J"
                    ],
                    "last": "Collins",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "",
            "volume": "609",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF17": {
            "ref_id": "b17",
            "title": "dengue virus in naturally infected human tissues, by immunohistochemistry and 616 in situ hybridization",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Guna",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Volkmar",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "C"
                    ],
                    "last": "Christianson",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "S"
                    ],
                    "last": "Hegde",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "J. Infect. Dis",
            "volume": "359",
            "issn": "",
            "pages": "1411--1418",
            "other_ids": {
                "DOI": [
                    "10.1126/science.aao3099"
                ]
            }
        },
        "BIBREF18": {
            "ref_id": "b18",
            "title": "Protein delivery using engineered virus-like particles",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "J"
                    ],
                    "last": "Kaczmarczyk",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Sitaraman",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "A"
                    ],
                    "last": "Young",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "H"
                    ],
                    "last": "Hughes",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "K"
                    ],
                    "last": "Chatterjee",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Proceedings of the 619 National Academy of Sciences",
            "volume": "108",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1073/pnas.1101874108"
                ]
            }
        },
        "BIBREF20": {
            "ref_id": "b20",
            "title": "Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF22": {
            "ref_id": "b22",
            "title": "A 625 single amino acid substitution in the West Nile virus nonstructural protein NS2A 626 disables its ability to inhibit alpha/beta interferon induction and attenuates virus 627 virulence in mice",
            "authors": [
                {
                    "first": "W",
                    "middle": [
                        "J"
                    ],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [
                        "J"
                    ],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "C"
                    ],
                    "last": "Clark",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Lobigs",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "A"
                    ],
                    "last": "Hall",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "A"
                    ],
                    "last": "Khromykh",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "Journal of Virology",
            "volume": "80",
            "issn": "",
            "pages": "2396--2404",
            "other_ids": {
                "DOI": [
                    "10.1128/JVI.80.5.2396-6282404"
                ]
            }
        },
        "BIBREF23": {
            "ref_id": "b23",
            "title": "CRISPR-Cas13d mediates robust RNA 630 virus interference in plants",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Mahas",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Aman",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Mahfouz",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Genome Biol",
            "volume": "20",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1186/s13059-019-1881-"
                ]
            }
        },
        "BIBREF26": {
            "ref_id": "b26",
            "title": "Genome editing in primary cells and in vivo using viral-derived Nanoblades 636 loaded with Cas9-sgRNA ribonucleoproteins",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Schaeffer",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Legube",
                    "suffix": ""
                },
                {
                    "first": "F.-L",
                    "middle": [],
                    "last": "Cosset",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Verhoeyen",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Ohlmann",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "P"
                    ],
                    "last": "Ricci",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Nat Commun",
            "volume": "635",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1038/s41467-018-07845-z"
                ]
            }
        },
        "BIBREF27": {
            "ref_id": "b27",
            "title": "Lentiviral Vectors for the 639 Treatment and Prevention of Cystic Fibrosis Lung Disease",
            "authors": [
                {
                    "first": "L",
                    "middle": [
                        "I"
                    ],
                    "last": "Marquez Loza",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "C"
                    ],
                    "last": "Yuen",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "B"
                    ],
                    "last": "Mccray",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Genes (Basel)",
            "volume": "640",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.3390/genes10030218"
                ]
            }
        },
        "BIBREF28": {
            "ref_id": "b28",
            "title": "Rewiring cellular 642 networks by members of the Flaviviridae family",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "J"
                    ],
                    "last": "Neufeldt",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Cortese",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "G"
                    ],
                    "last": "Acosta",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Bartenschlager",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Nat Rev Micro",
            "volume": "16",
            "issn": "",
            "pages": "125--142",
            "other_ids": {
                "DOI": [
                    "10.1038/nrmicro.2017.170"
                ]
            }
        },
        "BIBREF31": {
            "ref_id": "b31",
            "title": "A novel immortalized hepatocyte-like cell 647 line (imHC) supports in vitro liver stage development of the human malarial 648 parasite Plasmodium vivax",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Patrapuvich",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Hongeng",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Malar J",
            "volume": "17",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1186/s12936-018-2198-4"
                ]
            }
        },
        "BIBREF33": {
            "ref_id": "b33",
            "title": "Dengue reporter viruses reveal viral dynamics in interferon 651 receptor-deficient mice and sensitivity to interferon effectors in vitro",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "M"
                    ],
                    "last": "Rice",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Proceedings 652 of the National Academy of Sciences",
            "volume": "109",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1073/pnas.1212379109"
                ]
            }
        },
        "BIBREF36": {
            "ref_id": "b36",
            "title": "Visualization of retroviral replication in living cells reveals budding into 657 multivesicular bodies",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "4",
            "issn": "",
            "pages": "785--801",
            "other_ids": {
                "DOI": [
                    "10.1034/j.1600-0854.2003.00135.x"
                ]
            }
        },
        "BIBREF39": {
            "ref_id": "b39",
            "title": "Cas13b Is a Type VI-B CRISPR-Associated",
            "authors": [
                {
                    "first": "K",
                    "middle": [
                        "S"
                    ],
                    "last": "Koonin",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "V"
                    ],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF40": {
            "ref_id": "b40",
            "title": "RNA-Guided RNase Differentially Regulated by Accessory Proteins Csx27 and 662",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF42": {
            "ref_id": "b42",
            "title": "Lentivirus-delivered stable gene silencing by RNAi in primary 664 cells",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "A"
                    ],
                    "last": "Stewart",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "RNA",
            "volume": "9",
            "issn": "",
            "pages": "493--501",
            "other_ids": {
                "DOI": [
                    "10.1261/rna.2192803"
                ]
            }
        },
        "BIBREF44": {
            "ref_id": "b44",
            "title": "Multi-color fluorescent reporter dengue 667 viruses with improved stability for analysis of a multi-virus infection",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Pengon",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Siridechadilok",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "PLoS ONE",
            "volume": "668",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1371/journal.pone.0194399"
                ]
            }
        },
        "BIBREF46": {
            "ref_id": "b46",
            "title": "Massively parallel Cas13 screens reveal principles for guide RNA 671 design",
            "authors": [
                {
                    "first": "N",
                    "middle": [
                        "E"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nat. Biotechnol",
            "volume": "550",
            "issn": "",
            "pages": "1--6",
            "other_ids": {
                "DOI": [
                    "10.1038/s41587-020-0456-9"
                ]
            }
        },
        "BIBREF48": {
            "ref_id": "b48",
            "title": "Cas13d Is a Compact RNA-Targeting Type VI CRISPR Effector 674",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "A"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF49": {
            "ref_id": "b49",
            "title": "Positively Modulated by a WYL-Domain-Containing Accessory Protein",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF52": {
            "ref_id": "b52",
            "title": "Dynamic Imaging of RNA in Living Cells by CRISPR-Cas13",
            "authors": [
                {
                    "first": "L.-L",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF54": {
            "ref_id": "b54",
            "title": "Targeting of multiple reporter DENV2 with the crRNA array in single-virus 716 (left bar plot) and three-virus (right bar plot) infections. HAK = crRNA array shown in 717 a). The measurements for crRNA arrays were done in triplicate. The rest were done 718 in duplicate. d) Dose-response curves of multiplex VLP-Cas13b RNP generated with 719 a crRNA array",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF55": {
            "ref_id": "b55",
            "title": "Supplementary Figure 1: Flaviviral suppression with CRISPR-Cas13b by 725 inducible expression in BHK21. a) Diagram describing the inducible expression 726 system that controlled the expression of",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF56": {
            "ref_id": "b56",
            "title": "The top panel is the bright-field image of BHK21 expressing various form 729 of PspCas13b. The middle panel is the same views of the top panel but with anti-HA 730 signal representing the location of PspCas13b",
            "authors": [],
            "year": null,
            "venue": "PspCas13b, but not ER-localized PspCas13b, could suppress DENV2-mCherry 728 replication",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF57": {
            "ref_id": "b57",
            "title": "DENV2-mCherry intensity in BHK21 with crRNAs and different forms of PspCas13b",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF58": {
            "ref_id": "b58",
            "title": "Viral suppression for each reporter 734 DENV2 is shown as mean-fluorescent intensity (MFI) histograms from flow-735 cytometry measurement of infected cells. d) Specific viral suppression of reporter 736 DENV2 by mCh3 crRNA in co-infection setting. Viral suppression for each reporter 737 DENV2 is shown as heat-map scatter plot from flow-cytometry measurement of 738 infected cells. e) Summary bar plot of viral suppression activities of 51 crRNAs 739 individually tested. Viral suppression is presented as a mean of knock-down ratio 740 (KD ratio) calculated from the ratio of MFI in BHK21-Cas13b with experimental 741 crRNA relative to the MFI in BHK21-Cas13b with nontarget crRNA from duplicate 742 measurements (error bar = standard deviation)",
            "authors": [],
            "year": null,
            "venue": "Specific viral suppression of reporter DENV2 by an mCherry-targeting crRNA 733 (mCh3 crRNA) in single-virus infection setting",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF59": {
            "ref_id": "b59",
            "title": "The left bar 746 plot compare infectious titers of DENV2-16681 between BHK21-Cas13b with 8681 747 crRNA and BHK21-Cas13b with mCh3 crRNA (nontarget control) at 48 hours post 748 infection (hpi) and 72 hpi (error bar = standard deviation). The measurements were 749 done in duplicate",
            "authors": [],
            "year": null,
            "venue": "The right panel is representative bright-field images of the 750 infected cells at 48 and 72 hpi",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF60": {
            "ref_id": "b60",
            "title": "Supplementary Figure 2: VLP delivery of protein cargo into human primary 753 target cells. a) Diagram showing the generation of VLP for PspCas13b RNP 754 delivery (adapted from (Mangeot et al., 2019)). b) Delivery of YFP into various 755 mammalian cells. The figure show the results of transducing BHK21, hDC, macrophages, iMHC, and CD14+ monocytes with VLP-YFP from fluorescent 757 microscopy (bright-field images and fluorescent images) and percent transduction 758 measured by flow cytometry. c) Flow cytometry analysis of YFP delivery by VLP",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF61": {
            "ref_id": "b61",
            "title": "Supplementary Figure 3: The comparison of virus suppression activity 762 between 22-nt and 30-nt crRNAs and in vitro cleavage. a) crRNA set for 763 targeting fluorescent reporter genes. b) crRNA set for targeting NS5 gene of",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF62": {
            "ref_id": "b62",
            "title": "DENV2-16681. c) In vitro cleavage of mCherry RNA by PspCas13b + 22-nt mCh3",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "31 ribonucleoprotein (RNP) in nanomolar range to efficiently suppress dengue virus 32 infection in primary human target cells. Shortening spacer length could significantly 33 enhance RNA-targeting efficiency of PspCas13b in mammalian cells compared to 34 the natural length of 30 nucleotides without compromising multiplex targeting by a 35 CoV2 have prompted WHO to declare global health emergencies. Effective 43 antivirals and vaccines against these viruses are still being developed. CRISPR-44 Cas13, bacterial proteins that can be programmed to target specific RNA with 45 crRNA, are promising tools for developing programmable antivirals against RNA 46 viruses (Abbott et al., 2020; Aman et al., 2018a; 2018b; Bawage et al., 2018; Freije 47 et al., 2019). However, several challenges remain to translate it into practical use. 48 Transient delivery of Cas13b-crRNA into target cells is desirable for treating acute 49 viral infection to avoid the toxicity of long-term expression of Cas13 in the cells but 50 efficient delivery Cas13-crRNA into primary cells has not been achieved. Here, we 51 showed that transient delivery of Cas13b RNP in nanomolar range by virus-like 52 particle could efficiently suppress dengue virus infection in several primary human 53 cells. In contrast to previous studies in vitro and in bacteria, we found that 54 shortening spacer length of crRNA in the range of 26-18 nucleotides could enhance 55 knock-down activity by Cas13b in mammalian cells and did not compromise crRNA 56 processing and multiplex targeting capability. 57 58 Results 59 60",
            "latex": null,
            "type": "figure"
        },
        "FIGREF1": {
            "text": "68 promoter (EF1a) over several cell passaging (data not shown). To test virus 69 suppression, we utilized both fluorescent reporter viruses which provided virus-70 encoded fluorescent readout of virus replication(Schoggins et al., 2012; Suphatrakul 71 et al., 2018) and natural strains DENV2-16681 and ZIKV-SV0010(Buathong et al., 72 2015). We found that cytoplasmic PspCas13b with HIV-Rev nuclear export 73 sequence(Cox et al., 2017) could suppress DENV2-mCherry infection with an 74 mCherry-targeting crRNA (mCh3 crRNA, Supplementary table 1) and was chosen 75",
            "latex": null,
            "type": "figure"
        },
        "FIGREF2": {
            "text": "). While half of the crRNAs targeting fluorescent 85 reporter genes (6 out of 12) were effective at viral suppression, only a small fraction 86 of tiled crRNAs targeting the viral genes (3 out of 39, Supplmentary Figure 1e) 87 could efficiently suppress virus (knock-down ratio < 0.4). We further validated the 88 most efficient DENV2-targeting crRNA, 8681 crRNA, with DENV2-16681. We found 89 that it could reduce virus titer 15 folds relative to the nontarget crRNA at 48 hours 90 post infection (hpi) and was specific to DENV2-16681 as nontarget ZIKV-SV0010 91 was not affected (Supplementary Figure 1f, bar plot). Infected BHK21-Cas13b with 92 8681 crRNA were still actively dividing at 72 hpi (and potentially maintaining the 93 infectious titer in the media) while most BHK21-Cas13b with mCh3 crRNA were 94 dead from infection with dropping titer (Supplementary Figure 1f, bright-field image 95 panels",
            "latex": null,
            "type": "figure"
        },
        "FIGREF3": {
            "text": "human peripheral blood mononuclear cells (PBMC) over B cells and T cells 121(SupplementaryFigure 1c). VLP delivery of PspCas13b with 8681 crRNA (Figure 122",
            "latex": null,
            "type": "figure"
        },
        "FIGREF4": {
            "text": "1a) could suppress DENV2-16681 infection in human PBMC (Figure 1b). The 123 deliveries of ~77ng of Cas13b/100,000 cells (or 1.16 nM) at 2, 6, and 24 hours post 124 infection (hpi) were able to reduce dengue infection by half over the infection course 125 of 48 hours (Figure 1b). Together, these results show that VLP can be an effective 126 way to deliver antiviral Cas13b RNP into primary human target cells to reduce 127 dengue infection. 128 129 Our results in Supplementary Figure 1e also suggested that the knock-down 130 efficiency could be improved for several targets. Using BHK21-Cas13b, we tested 131 whether spacer length could affect viral suppression efficiency for a subset of these 132 crRNAs. Strikingly, shortening spacer length to 26-18 nucleotides of mCh3 crRNA 133 could drastically enhance the suppression of DENV2-mCherry with maximum knock-134 down activity achieved between 20 and 22 nucleotides and without cross 135suppressing nontarget DENV2-mAmetrine(Figure 2a). We also found that 22-136 nucleotide spacer length could activate a ZIKV NS2A target region that was inactive 137 against any crRNAs with 30-nucleotide spacer (30-nt crRNA) tiled against it (Figure 138",
            "latex": null,
            "type": "figure"
        },
        "FIGREF5": {
            "text": "2b). None of the 30-nt crRNAs could suppress ZIKV beyond knock-down ratio of 139 0.8, while at least three 22-nt crRNAs could go beyond knock-down ratio of 0.5 140 (Figure 2b). Shortening spacer enhanced the knock-down activity of several 141 crRNAs with varying efficiency",
            "latex": null,
            "type": "figure"
        },
        "FIGREF6": {
            "text": ". 22-nt 8681 crRNA also did 151 not show any deterioration of knock-down activity as observed in BHK21-Cas13b 152 (Supplementary Figure 3b and Figure 2c). These results together show that short 153 spacer length could enhance the antiviral activity of PspCas13b and did not 154 compromise its specificity. 155 156 We tested whether the enhancement effect of short spacer could be observed in 157 different settings. VLP delivery of Cas13b with 22-nt mCh3 crRNA to 293T, hDC, 158 and iMHC showed superior knock-down activity over its 30-nt counterpart with 159 Cas13b dose at 126ng/100,000 cells (Figure 2d), indicating that the effect was not 160 cell-specific. In BHK21-Cas13b, 22-nt mCh3 crRNA could knock down 161 overexpressed mCherry reporter gene while 30-nt crRNA could not (Figure 2e), 162 suggesting that the effect was applicable to regular mRNA. Interestingly, in vitro 163 cleavage of mCherry RNAs by PspCas13b was aggravated by 22-nt crRNA 164 (Supplementary Figure 3c), suggesting that the effect was specific to mammalian 165 cells. 166 167 Since natural spacer lengths found in crRNA array of CRISPR-Cas13b in bacteria 168 are no shorter than 30 nucleotides(Cox et al., 2017; Smargon et al., 2017), we tested 169 whether 22-nt spacer could affect crRNA processing and multiplex targeting by a 170 crRNA array (Figure 3a). In vitro crRNA processing of 22-nt and 30-nt arrays with 171 PspCas13b were equally efficient (Figure 3b). Multiplex targeting of fluorescent 172 reporter DENV2 could also be achieved with 22-nt crRNA array in both BHK21-173 Cas13b (Figure 3c) and in VLP formats (Figure 3d). Multiplex targeting by both 30-174 nt and 22-nt crRNA arrays reduced knock-down efficiency for each reporter virus 175 slightly compared to the single-virus targeting with single crRNAs (Figure 3c, left bar 176 plot). 22-nt crRNA array generally suppressed reporter DENV2 more than 30-nt 177 crRNA array in both single-virus (Figure 3c, left bar plot) and triple-virus (Figure 3c, right bar plot) infections. Dose-response curves of multiplex VLP generated with a 179crRNA array showed that more Cas13b was required to achieved the same level of 180 suppression compared to Cas13b-single crRNA by 3-10 folds(Figure 3dvs.Figure 1813c). 22-nt crRNAs still suppressed viruses more than their 30-nt counterparts, 182 though the enhancement effect of 22-nt spacer for mAmeterine was drastically 183 reduced in the multiplex targeting(Figure 3d vs. Figure 2c). 184185Discussion 186 187In summary, we characterized the antiviral efficiency of CRISPR-Cas13b in 188 suppressing DENV2 and ZIKV infection in mammalian cells (SupplementaryFigure 189",
            "latex": null,
            "type": "figure"
        },
        "FIGREF7": {
            "text": "1). We showed that transient Cas13b RNP delivery by VLP could effectively 190 suppress dengue infection in both cell lines and primary human target cells (Figures 191 1b and 2d). We found that shorter spacer length could significantly improve the 192 knock-down activity of CRISPR-Cas13b in mammalian cells and increased the 193 number of targetable sites (Figure 2). The short spacer length (22-nt) did not affect 194 crRNA processing and still enabled multiplex targeting with crRNA array (Figure 3). 195 196 Our results demonstrated the effectiveness of transient delivery of PspCas13b RNP 197 by VLP in reducing dengue infection in human primary target cells. VLP delivery of 198 Cas13b RNP delivery could negate several limitations such as genotoxicity and 199 gene-size restriction imposed by gene delivery vectors such as lentivirus and AAV. 200 Previous studies have shown that Cas13 RNP or RNA delivery could suppress RNA 201 virus infection but the delivery methods by electroporation and transfection are not 202 suitable for in vivo and could be highly toxic to primary cells (Bawage et al., 2018; 203 Freije et al., 2019). Our results show that VLP delivery could effectively deliver 204 Cas13b RNP into a variety of cells without high toxicity. Our results showed that with 205 the right crRNAs, a picomolar range of PspCas13b could achieve strong suppression 206 of dengue infection (e.g. 30 ng of PspCas13b per 100,000 cells (or 452 pM of 207 PspCas13b) with 22-nt mCh3 crRNA and 22-nt mAmet1,Figure 2c). In case of 208 primary human PBMC, we were able to halve DENV2 infection with ~77 ng of 209Cas13b/100,000 PBMC (or IC50 ~ 1.16 nM) even during ongoing infection (Figure 210",
            "latex": null,
            "type": "figure"
        },
        "FIGREF8": {
            "text": "1b). The effective dose of VLP-PspCas13b RNP could rival some of the best 211 performing small-molecule antivirals, but with added benefit of programmability. 212Our results highlight a distinct difference between CRISPR-Cas13b RNA targeting in 214 mammalian cells and in vitro/bacteria. Consistent with our study, shortening spacer 215 length between 18-26 nucleotides did not appear to reduce PspCas13b binding to 216 target RNA in mammalian cells as shown by previous live-imaging study using 217 dCas13b-fluorescent fusion proteins(Yang et al., 2019). In contrast, our results of in 218 vitro cleavage by PspCas13b(Supplementary Figure 3c)and previous 219 characterizations of other Cas13b by in vitro cleavage and in bacteria showed that 220 optimal spacer length coincides with natural spacer length of 30 221 nucleotides(Gootenberg et al., 2018; Smargon et al., 2017). In contrast to Cas13b 222 and Cas13a, Cas13d naturally utilizes varying spacer lengths and was not affected 223 by short spacer length in all settings (Konermann et al., 2018; Wessels et al., 2020; 224 Yan et al., 2018). Despite the general benefits of short spacer lengths for 225 PspCas13b in mammalian cells, there were cases where they aggravated knock-226 down activities. These exceptions were noticed only in the setting of overexpressed 227 Cas13b and crRNA in BHK21-Cas13b (Supplementary Figure 3), but not in the 228 setting of VLP delivery (Figure 2c). There were notable differences between the two 229 delivery methods such as the dosage and the dynamics of Cas13b and crRNA in the 230 cells. In VLP delivery, crRNA was pre-assembled with Cas13b before introduction 231 into target cells while unbound crRNA could be present in the overexpression 232 setting. In VLP delivery, the CRISPR-Cas13 components may stay only in the 233 cytoplasm of targeted cells while crRNA in overexpression setting were produced in 234 nucleus of targeted cells. Additional investigations will be needed to understand how 235 these differences could affect the RNA targeting by CRISPR-Cas13b as they are 236 relevant for designing effective delivery strategies. 237 238 Previous crRNA-scanning studies have shown that only a small fraction of target 239 regions on mRNA in mammalian cells was targetable by CRISPR-Cas13(Abudayyeh 240 et al., 2017; Freije et al., 2019; Wessels et al., 2020). These studies utilized a tiling 241 crRNA library with a fixed spacer length to reveal the factors that determined the 242 knock-down efficiency of a crRNA. Our results (Figure 2b and Supplementary 243 suggest that varying spacer length in a scanning analysis could improve 244 the number of targetable regions for CRISPR-Cas13b and might uncover additional 245 factors that determine the knock-down efficiency of a crRNA. Combining this 246 strategy with targeting conserved sites on viral RNA(Abbott et al., 2020; Freije et al., 247 2019) has the potential to identify highly potent antiviral crRNAs. 248 249 Several studies have demonstrated the use of CRISPR-Cas13 to target both 250 plant(Aman et al., 2018a; Mahas et al., 2019) and animal(Abbott et al., 2020; 251 Bawage et al., 2018; Freije et al., 2019) RNA viruses. Our study contributes the 252 implementation of potent virus inhibition by PspCas13b RNP with short spacer and 253 transient delivery by VLP in human primary cells. Our results are relevant to several 254 emerging RNA viruses such as SARS-CoV2 that replicates in the cytoplasm. A long 255 line of gene therapy studies to treat cystic fibrosis using lentivirus delivery in vivo 256 supports the possibility of using pseudotyped Cas13b-VLP to treat viral infection in 257 lung and respiratory track(Marquez Loza et al., 2019). In addition to RNA viruses, 258 our results are applicable to knocking down specific host genes in primary cells for 259 Cells and culture media: BHK21, BHK21-rtTA3(Suphatrakul et al., 2018), and 265 293T were cultured in high-glucose DMEM (HyClone) supplemented with 10% heat-266 inactivated fetal bovine serum (HI-FBS, ThermoFisher Scientific), 100 U/ml penicillin-267 G, and 100 \u00b5g/ml streptomycin sulfate (ThermoFisher Scientific) (D10). Vero cells 268 was maintained in MEM (ThermoFisher Scientific) supplemented with 10% HI-FBS 269 and 100 U/ml penicillin-G, and 100 \u00b5g/ml streptomycin sulfate (MEM10). iMHC was 270 maintained in DMEM-F12 (Hyclone) supplemented with 10% HI-FBS). C6/36 was 271 maintained in Leibovitz L-15 (HyClone) supplemented with 10% HI-FBS, 10% 272 tryptose phosphate broth (Sigma), and 100 U/ml penicillin-G, and 100 \u00b5g/ml 273 streptomycin sulfate. Human primary PBMC, macrophages, and CD14 + monocytes 274 were maintained in RPMI-1640 (HyClone) supplemented with 10% HI-FBS, 100 U/ml 275 penicillin-G, and 100 \u00b5g/ml streptomycin sulfate (R10). All the adherent cells in this 276 study were detached by 0.1% Trypsin-EDTA (ThermoFisher Scientific). All 277 mammalian cells were cultured in 5% CO2 at 37\u00b0C with at least 80% humidity. C6/36 278 was cultured at 28\u00b0C. 279 Primary human PBMC were obtained from fresh blood of healthy volunteers. Human 281 blood was obtained from donors after providing informed consent, following a 282 protocol (Siriraj-IRB COA no. Si707/2016, Protocol number: 632/2559 (EC2)) 283 approved by Faculty of Medicine, Siriraj Hospital, Mahidol University, Thailand. The 284 blood was diluted 1:1 ratio of normal saline and layered over Lymphoprep\u2122 (Axis-285 shield) gradient density at 1,077 g/ml. After centrifugation at 800 x g for 25 minutes 286 (min) at room temperature (RT), plasma samples were removed from the top of the 287 solution and PBMC were recovered from the underlying layer. The PBMC were 288 washed twice in RPMI 1640 medium and then incubated with red blood cells lysis 289 buffer at room temperature for 5 minutes to lyse contaminating RBCs. The PBMC 290 were washed once in R10. PBMC viability, measured by trypan blue exclusion, was 291 greater than 95%. 292 293 Human dendritic cells (hDC) were derived from PBMC according to published 294 protocol (Boonnak et al., 2011). 1.5 x 10 7 of PBMC were seeded on each 60 mm-295 Primaria plate (Corning) and cultured for 1 hour. Cells were washed with 5 ml of 296 plain RPMI, 10 times to remove non-adherent cells. Washed PBMC was then 297 replenished with 5 ml of R10 supplementing with 2,000 U/ml of rh GM-CSF 298 (ThermoFisher Scientific) and 4,000 U/ml of rh IL-4 (R&D Systems) and cultured for 299 5 days. DC were then harvested from culture supernatant for experiments and 300 analysis. DC were verified with a panel of CD14-PerCP (Miltenyl Biotech), CD83-301 BV510 (BD Pharmingen), CD86-PE (BD Pharmingen), HLA-DR-APC-Vio770 302 (Miltenyl Biotech), CD209-PE-Vio770 (Miltenyl Biotech), and CD163-FITC 303 (BioLegend) mAbs by flow cytometry (BD LSRFortessa). 304 305Fresh PBMC were used to isolate primary monocytes using Dynabeads\u00ae 306Untouched\u2122 Human Monocytes (ThermoFisher Scientific) according to the 307 manufacturer's instructions. Briefly, the PBMC were incubated with blocking reagent 308 and antibody mixture for 20 min at 2 to 8 \u00b0C to label cells which were not monocytes. 309The labeled cells were mixed with Dynabeads\u00ae and incubated for 15 min at 2 to 8 310 \u00b0C. To remove nonmonocytes, the labeled cells were placed in a magnet 311 (DynaMag\u2122). The purity of the isolated monocyte subsets, evaluated by flow 312 cytometry with CD14-PerCP mAb (Miltenyl Biotech)",
            "latex": null,
            "type": "figure"
        },
        "FIGREF9": {
            "text": "317 Half volume of medium was replaced with fresh medium every 3 days. The 318 macrophages were harvested for experiments on day 13. The macrophages were 319 then verified by flow cytometry analysis with CD163-FITC mAb (Biolegend). 320 321 Plasmids: Spacer sequences used to construct crRNAs are listed in 322 Supplementary table 1, Figure 2, and Supplementary Figure 3. All the plasmids 323 were constructed by either Gibson assembly or standard T4 ligation. 324 325 PspCas13b from pC0046(Cox et al., 2017) (Addgene #103862) was subcloned to 326 replace CasRx on pXR001(Konermann et al., 2018) (Addgene #109049). The 327 pXR001-PspCas13b was then engineered to replace HIV NES with VAMP2 (amino-328 acid sequence = KTGKNLKMMIILGVICAIILIIIIVYFTGSR) or SQS (amino-acid 329 sequence = SRSHYSPIYLSFVMLLAALSWQYLTTLSQVTED) to generate lentiviral 330 plasmids for PspCas19-VAMP2 and PspCas13-SQS. These pXR001-Cas13b 331 plasmids were used for the experiment in Figure 1b. 332 333 To create lentiviral vector with inducible expression of Cas13b, PspCas13b from 334 pC0046(Cox et al., 2017) (Addgene #103862) was subcloned into 335 pENTR1A(Campeau et al., 2009) (Addgene #17398) at EcoRI site. PspCas13b on 336 pENTR1A was shuttled to pLenti-CMVtight-Blast-DEST(Campeau et al., 2009) 337 (Addgene #26434) with Gateway cloning (ThermoFisher Scientific). Blasticidin 338 resistant gene was then replaced with eGFP for the purpose of cell sorting. This339pLenti-PspCas13b plasmid was used to generate lentivirus for deriving BHK21-340 Cas13b stable cell line. 341 342 pBA439(Adamson et al., 2016) (Addgene #85967) was engineered to replace Cas9-343 gRNA cassette with Psp direct repeat (DR) with BsmBI sites upstream for cloning 344 spacer and to replace BFP with miRFP703 for the purpose of cell sorting. The lentiviral plasmid, pBA439-Psp-miRFP was then used for testing crRNAs in plasmid for PspCas13b RNP delivery by VLP, BIC-Gag-CAS9(Mangeot et 349 al., 2019) (Addgene #119942) was engineered to replace Cas9 with PspCas13b-HA 350 to generate BIC-Gag-PspCas13b. pC0043 (Addgene #103854) was used to clone 351 spacer to generate a crRNA for VLP production. 352 353 PspCas13b on pC0068 plasmid (Addgene # 115219) was replaced with PspCas13b 354 with HIV NES and HA tag (from pC0046 (Addgene #103862)) to generate pC0068-355 PspCas13b-HA for PspCas13b-HA purification. 356 357 crRNA arrays (mCh3-mAmet1-mK1) was generated from T4 ligation of 3 pairs of 358 annealed primers with asymmetric, unique overhangs to pBA439-Psp-miRFP 359 linearized with BsmBI for experiments in BHK21-Cas13b. The crRNA arrays were 360 then subcloned onto pC0043 linearized with BbsI and XhoI to generate pC0043-361 crRNA array plasmid for multiplex VLP generation.362 363 Viruses: DENV2-16681 and ZIKV-SV0010/15(Buathong et al., 2015) were produced 364 from C6/36 cell line cultured in L-15 (HyClone) supplemented with 1.5% HI-FBS 365(ThermoFisher Scientific), 10% tryptose phosphate, and 100 U/ml penicillin-G, and 366 100 \u00b5g/ml streptomycin sulfate. The infectious titers were quantitated by foci assay 367in Vero cells stained with anti-E 4G2 monoclonal antibody as previously 368 described(Suphatrakul et al., 2018). Fluorescent reporter DENV2 were generated 369 and quantitated as previously described(Suphatrakul et al., 2018).370 371 Lentivirus for gene delivery: Pseudotyped lentivirus particles were generated by 372 co-transfection of lentiviral plasmids (e.g. pBA439-Psp-miRFP and pLenti-CMVtight-373 PspCas13b-eGFP) with pCMV-VSV-G(STEWART, 2003) (Addgene #8454) and 374 psPAX2 (Addgene #12260) using PEI into 293T cells cultured in D10. The media 375 was harvested for lentivirus particles 2 days post transfection. 376 377 Immunofluorescent microscopy: Briefly, cells were seeded in a 96 well plate to 378 reach 50-60 % confluency overnight. Cells were washed and fixed with 100 \u00b5L 4% paraformaldehye in PBS for 10 minutes at 37\u00b0C, permeabilized with 100 \u00b5L 1% 380 Triton X-100 in 1x PBS for 15 minutes at 37\u00b0C, and blocked with 1% BSA in 1x PBS 381 for 1 hour at 37\u00b0C . Cells were then incubated with primary antibody (HA-Tag Mouse 382 mAb Cell Signaling, 1:100 dilution), washed and incubated with secondary antibody 383 (Cy3 conjugated goat anti-mouse (Jackson ImmunoResearch), 1:2000 dilution). 384 Samples were washed and images were obtained using EVOS fluorescence 385 microscope (ThermoFisher Scientific). 386 387 Testing crRNAs with Cas13b inducible expression system in BHK21: BHK21-388 rtTA3 cell line(Suphatrakul et al., 2018) was transduced with lentivirus generated 389 from pLenti-PspCas13b. Transduced cells (GFP + ) were sorted into single cells to 390 isolate stable clones on BD FACSAria III. To screen for desired clone (BHK21-391 Cas13b), we tested the clones for uniform Cas13b expression and their abilities to 392 knock down DENV2-mCherry with mCh3 30-nt crRNA. A BHK21-Cas13b clone was 393 selected for all subsequent experiments. crRNA was introduced into the BHK21-394 Cas13b clone with the lentivirus carrying mU6-crRNA expression cassette and 395 miRFP703-2A-puromycin cassette for cell sorting. Cells that were positive for both 396 GFP (PspCas13b) and miRFP703 (crRNA) were sorted as a pool. The pool cells 397 were maintained for at least a week under D10 + 5 \u00b5g/ml puromycin before the 398 knock-down experiments. To test for knock-down, 100,000 cells/well were seeded in 399 6-well plate with D10 + 0.1 \u00b5g/ml of doxycycline to induce Cas13b expression. After 400 24 hours, the induced cells were then infected with DENV2 or ZIKV at M.O.I. = 0.1 to 401 test for knock-down activity of the crRNA. The cells were maintained at 37\u00b0C for 72 402 days before harvested by trypsin digestion and fixed with 3.7% formaldehyde in 1x 403 PBS for measurement of virus infection by flow cytometry (BD LSRFortessa). 404 405 Virus infection was measured by mean fluorescent intensity (MFI) of fluorescent 406 reporters (for reporter DENV2 such as DENV2-mCherry, DENV2-mAmetrine, and 407 DENV2-LSSmKate2) or viral E antigens (stained with 4G2 mAb for DENV2-16681 408 and ZIKV-SV0010/15) of total cells or percent infection of total cells. For knock-409 down ratio (KD ratio), MFI (or percent infection of total cells) of BHK21-Cas13b with 410 an experimental crRNA was divided by the MFI (or percent infection of total cells) of 411 BHK21-Cas13b with a non-targeting crRNA. 412 Production of VLP-YFP and VLP-Cas13b RNP: 17-million 293T cells were seeded 414 in 150-mm dish. To generate VLP-Cas13b RNP, one dish of 293T was transfected 415 with four plasmids 5.1 \u00b5g BIC-Gag-PspCas13b, 13.2 \u00b5g pC0043-crRNA, 3.3 \u00b5g 416 pCMV-VSV-G (STEWART, 2003) (Addgene #8454) and 8.4 \u00b5g pBS-CMV-gagpol 417 (Addgene #35614) using 90 \u00b5g 1mg/ml PEI (3ug PEI: 1ug total DNA) 24 hours after 418 seeding. For VLP-YFP, BIC-Gag-PspCas13b and pC0043-crRNA were replaced 419 with 5.1 \u00b5g MLV-Gag-YFP(Sherer et al., 2003) (Addgene #1813). The transfected 420 cells were maintained for 2 days before harvest of media. Harvested media was 421 clarified by centrifugation at 1000 x g, 4\u00b0C, 10 minutes and then filtered with 0.45-\u00b5m 422 PES-membrane syringe filter (Millipore). 30 ml of clarified media was then layered on 423 10 ml of 10% w/v sucrose cushion in 1xPBS in 50-ml falcon tube (Corning) and 424 centrifuged at 10000 xg, 4\u00b0C for 4 hours in JA14 rotor. The supernatant was 425 carefully discarded and dried by pressing against paper towel for 30 seconds. The 426 pellet was resuspended with D10. Dissolved pellet was aliquoted and stored frozen 427 at -70\u00b0C. 428 429 Purification of PspCas13b and quantitation of PspCas13b in VLP: PspCas13b-430 HA was expressed and purified as previously reported with some 431 modifications(Gootenberg et al., 2018). PspCas13b-HA was expressed in BL21-432 Rossetta2 by 2mM IPTG induction in 2xYT media at O.D. of 0.6, 22\u00b0C for 18 hours. 433 The bacteria cells were harvested by centrifugation and stored at -70\u00b0C until 434 purification. The bacteria pellet was resuspended in 20mM Tris-HCl pH 8.0, 500mM 435 NaCl, 1mM DTT + protease inhibitors (EDTA-free, Roche) + lysozyme, lysed by 436 sonication, and clarified by centrifugation at 10,000 xg, 4\u00b0C for 20 minuted. Clear 437 lysate was loaded onto streptactin column. The column was then washed with 438 20mM Tris-HCl pH 8.0, 500mM NaCl, 1mM DTT before elution with the same buffer 439 + 0.15% NP-40 + 2.5 mM desthiobiotin. The eluted fraction was treated with Ulp1 440 protease to cleave affinity tag overnight at 4\u00b0C. Ulp1 and cleaved affinity tag were 441 removed by NiNTA (Roche). The NiNTA flow through was adjusted to 250mM NaCl 442 and purified on HiTRAP-SP (20mM HEPES pH 7.3, 250mM NaCl, 5% glycerol, 1mM 443 DTT). We obtain highly purified PspCas13b-HA that was used as Cas13b reference 444 for VLP quantitation and in vitro crRNA processing. 445 To quantitate for Cas13b in VLP, 2 \u00b5l from serial dilutions of pure PspCas13b-HA 447 and VLP were dotted on a strip of nitrocellulose membrane. The membrane was 448 blocked with 5% skim milk in 1xPBS-T. The blocked membrane was then probed 449 with anti-HA (1:1000 dilution, CellSignalling) and rabbit anti-mouse P260 IgG 450 conjugated with HRP (1:1000 dilution, DAKO). The antibody-stained membrane was 451 then soaked with SuperSignal West Pico PLUS substrate (ThermoFisher Scientific) 452 according to manufacturer's instruction and imaged on C-Digit blot scanner (LI-453 COR). Quantitation of signal was performed with Image Studio Lite program (LI-454 COR). 455 456 Delivery of protein cargo by VLP: VLP delivery media was prepared by mixing a 457 volume of VLP preparation according to the desired Cas13b dose and topped up 458 with D10 to 100 \u00b5l. For VLP-YFP, 50 \u00b5l of VLP preparation was mixed with 50 \u00b5l 459 D10. To deliver VLP into BHK21, iMHC, and 293T cells, the cells (BHK21 ~100,000 460 cells; 293T ~150,000-200,000 cells) in one well of 24-well plate were treated with 461 300 \u00b5l of complete media + 8 \u00b5g/ml polybrene for 10 minutes at 37\u00b0C before adding 462 100 \u00b5l of VLP delivery media. For these cells, the VLP-treated cells were then 463 maintained for 24 hours at 37\u00b0C before exchanging media to 500 \u00b5l D10 for another 464 24 hours before harvest for analysis. To deliver VLP into hDC, 50,000 cells of hDC 465 were centrifuged at 450xg, 5 minutes, 4\u00b0C and the cell pellet was resuspended with 466 300 \u00b5l R10+ 8 \u00b5g/ml polybrene. 100 \u00b5l of VLP delivery media (R10) was added to 467 hDC. The cells were then transferred to one well of 24-well plate and cultured for 48 468 hours at 37\u00b0C before harvest. VLP delivery of YFP was performed with the same 469 protocol as VLP delivery of Cas13b. 470 471 Test of knock down in hDC, 293T, iMHC by VLP: For iMHC and BHK21, 25,000 472 cells/well were seeded on 24-well plate. For 293T, 50,000 cells/well were seeded on 473 24-well plate. After 24 hours, the cells were infected with DENV2-mCherry at MOI 474 0.1 for another 24 hours. VLP was then delivered as detailed above. For hDC, cell 475 suspension (~50,000 cells/20 \u00b5l) was mixed 30 \u00b5l of DENV2-mCherry (MOI = 1.0) 476 and topped up with 50 \u00b5l R10 in 1.5-ml Eppendorf tube and incubated at 37\u00b0C for 2 477hours. Then, the cells were washed once with 50 \u00b5l R10 by centrifugation at 450xg, 478 5minutes, 4\u00b0C and proceeded to VLP delivery. 479Test of knock down in BHK21 with overexpressed mCherry reporter: BHK21-481Cas13b cell line was transduced with lentivirus carrying TRE-mCherry reporter 482 cassette (generated from pLV-tetO-mCherry, Addgene #70273). The transduced 483 cells were sorted for mCherry+ cells. The BHK21-Cas13b-mCherry was then 484 transduced with crRNA lentivirus and sorted for GFP + mCherry + miRFP703 + cells. 485The sorted cells were maintained in D10+5 \u00b5g/ml puromycin for 1 week before 486knock-down experiment. The knock down was initiated by adding 0.1 \u00b5g/ml 487 doxycycline and continued the culture for 48 hours. The cells were harvested by 488 trypsin digestion and fixed with 3.7% formaldehyde in 1xPBS for analysis by flow 489 cytometry. 490 491 DENV2 knock down in infected human peripheral blood monocytes: PBMCs 492 were obtained as detailed above. The experiments were performed in 24-well plate 493 with PBMC seeded at 100,000 cells/well in R10. To infect PBMC with DENV2-494 16681, 0.1 mg/ml of purified 4G2 (Flavivirus E protein specific mAbs) were incubated 495 with virus for one hour at 37\u00b0C before adding to PBMCs at MOI of 1 in R10. PBMC 496 were infected for 2 hours at 37\u00b0C. To deliver VLP, 200 \u03bcl of culture media was 497 removed and 100 \u03bcl of R10 with 8 \u03bcg/ml polybrene was added to the well. PBMC 498 were treated with polybrene at 37\u00b0C for 10 minutes before 100 \u03bcl of VLP delivery 499 media was added. Infected PBMC were cultured for 48 hours post infection before 500 harvest for analysis. The culture media was also collected and clarified by 501 centrifugation at 4\u00b0C for foci assay to quantitate infectious virus titer. 502 503 Harvested PBMCs were washed and stained with live dead dye (Invitrogen) 504 according to manufacturer's instruction. Stained cells were fixed and permeabilized 505 with 3.7% formaldehyde and 0.5% saponin, respectively. Cells were then 506 intracellularly stained with 4G2 mAbs followed by rabbit anti-mouse Igs FITC (Dako). 507 The cells were fixed with 1% formaldehyde and analyzed on BD LSRFortessa. Data 508 analysis was performed using FlowJo software version 10.1. 509 510 For testing the uptake of VLPs in PBMCs, cells were incubated with YFP-VLPs 50 \u00b5l 511 for 48 hrs at 37\u00b0C. Cells were washed and surface stained with CD3 APC (BD 512 Pharmingen), CD14 PerCP (BD Pharmingen) and CD19 PE (Dako) mAbs for 30 min. 513 Thereafter, cells were washed, fixed with 1% formaldehyde and analyzed on BD 514 LSRFortessa. Data analysis was performed using FlowJo software version 10.1. 515 516 In vitro transcription and crRNA processing assay: DNA template for in vitro 517 transcription of a crRNA array was amplified from pBA439-HAK by PCR using a 518 forward primer with T7 promoter sequence and a reverse primer that included poly-T 519 to terminate transcription. 0.5 \u00b5g of DNA template were transcribed in 100 \u00b5l 520 reaction using 30 \u00b5g T7 RNAP, 2mM NTPs, 40 U RNaseIN (Promega) in 50mM Tris-521 HCl pH 7.5, 15mM MgCl2, 5mM DTT, and 2mM spermidine at 37\u00b0C for 2 hours. The 522 transcription reaction was treated with 2 U of DNase I (ThermoFisher Scientific) at 523 37\u00b0C for 30 minutes and clean-up using Qiagen RNA easy kit according to 524 manufacturer's protocol. In vitro crRNA array processing was carried out in 10 mM 525 Tris-HCl pH 7.5, 50 mM NaCl, 0.5 mM MgCl2, 20U RNaseIN (Promega), 0.1% BSA 526 for 30 minutes at 37\u00b0C, stopped by adding 1% SDS, 2x TBE-Urea gel loading buffer 527 and denatured for 10 minutes at 95\u00b0C. Samples were then put on ice for 10 minutes 528 before running them on an 12% TBE-8 M Urea polyacrylamide gel in 1x TBE buffer 529 at 200 V for 40 minutes. Gel staining was carried out in 1x Sybr Gold in 1x TBE for 5 530 minutes and imaged on a gel doc system. 531 532 In vitro cleavage of target RNA by PspCas13b: Cas13b-cRNARNP was formed by 533 mixing 1 or 2 uM of crRNA with 1.8 uM of Cas13b and incubate on ice 10 min in 5 \u00b5l 534 water. The preformed RNP was then added to 10 \u00b5l in vitro cleavage reaction that 535 contained 20 ng of mCherry RNA, 1 ul of 10x Cut smart buffer (NEB), 4U of RNase 536 IN and incubated at 37\u00b0C for 2 hours. The reaction was stop with 1%SDS and then 537 extracted by phenol/chloroform for ethanol precipitation. The RNA pellet was 538 resuspended with 1X RNA loading buffer (4 mM EDTA, pH 8.0, 2.7% formaldehyde, 539 20% glycerol, 7.7 M formamide, 80 mM MOPS, 20 mM sodium acetate 540 0.025% (v/v) bromophenol blue) and heated at 95\u00b0C for 10 minutes and then put on 541 ice 2 minutes before loading on 8% TBE-polyacrylamide gel with 8 M urea. 542 543 Acknowledgement and conflict of interest: We would like to acknowledge 544 Nuntaya Punyadee for technical assistance with human macrophages and iMHC 545 cultures; Korbporn Boonnak for her technical advice on human dendritic cells; Sutha Sangiambut for assistance with chemiluminescent measurement. This study was 547 funded by a research grant from Platform Technology Program, BIOTEC (, T.R., Dhamdhere, G., Liu, Y., Lin, X., Goudy, L., Zeng, L., Chemparathy, A., 554 Chmura, S., Heaton, N.S., Debs, R., Pande, T., Endy, D., La Russa, M., Lewis, 555 D.B., Qi, L.S., 2020. Development of CRISPR as a prophylactic strategy to 556 combat novel coronavirus and influenza. bioRxiv 10, 2020.03.13.991307. 557 doi:10.1101/2020.03.13.991307 558 Abudayyeh, O.O., Gootenberg, J.S., Essletzbichler, P., Han, S., Joung, J., Belanto, 559 J.J., Verdine, V., Cox, D.B.T., Kellner, M.J., Regev, A., Lander, E.S., Voytas, 560 D.F., Ting, A.Y., Zhang, F., 2017. RNA targeting with CRISPR-Cas13. Nature 561 391, 806. doi:10.1038/nature24049 562 Adamson, B., Norman, T.M., Jost, M., Cho, M.Y., Nu\u00f1ez, J.K., Chen, Y., Villalta, 563 J.E., Gilbert, L.A., Horlbeck, M.A., Hein, M.Y., Pak, R.A., Gray, A.N., Gross, C.A., 564 Dixit, A., Parnas, O., Regev, A., Weissman, J.S., 2016. A Multiplexed Single-Cell 565 CRISPR Screening Platform Enables Systematic Dissection of the Unfolded 566 Protein Response. Cell 167, 1867-1882.e21. doi:10.1016/j.cell.2016.11.048 567 Aman, R., Ali, Z., Butt, H., Mahas, A., Aljedaani, F., Khan, M.Z., Ding, S., Mahfouz, 568 M., 2018a. RNA virus interference via CRISPR/Cas13a system in plants. 569 Genome Biol. 19, 234. doi:10.1186/s13059-017-1381-1 570 Aman, R., Mahas, A., Butt, H., Ali, Z., Aljedaani, F., Mahfouz, M., 2018b. 571 Engineering RNA Virus Interference via the CRISPR/Cas13 Machinery in 572 Arabidopsis. Viruses 10, 732. doi:10.3390/v10120732 573 Aye, K.S., Charngkaew, K., Win, N., Wai, K.Z., Moe, K., Punyadee, N., Thiemmeca, 574 S., Suttitheptumrong, A., Sukpanichnant, S., Prida, M., Halstead, S.B., 2014. 575 Pathologic highlights of dengue hemorrhagic fever in 13 autopsy cases from 576 Myanmar. Hum. Pathol. 45, 1221-1233. doi:10.1016/j.humpath.2014.01.022 577 Bawage, S.S., Tiwari, P.M., Santangelo, P.J., 2018. Synthetic mRNA expressed 578 Cas13a mitigates RNA virus infections. bioRxiv 21-22, 370460. 579 doi:10.1101/370460 Efficient suppression of DENV2 infection in primary target cells by 684 PspCas13b RNP delivered via virus-like particles (VLP). a) Diagram describing 685 the experimental setup of Cas13b RNP delivery into human PBPMC infected with 686 DENV2-16681. b) The antiviral activity of PspCas13b + 8681-nt crRNA against 687 DENV2-16681 in PBMC. Cas13b RNP was delivered by VLP at 0, 6, or 24 hours 688 post infection (hpi). Left histogram is a representative result from PBMC of one 689 donor at 24 hpi VLP delivery. DV = the level of dengue E antigen measured by anti-690 E 4G2 mAb. Right bar plot displays DENV2 suppression with 8681 crRNA and 691 mCh3 crRNA (nontarget control). The VLPs were delivered with equal Cas13b dose 692 of ~77ng/100,000 cells. Knock-down ratio was calculated by the frequencies of 693 infected cells of the VLP condition divided by the frequency of infected cells without 694 VLP. The results represent the data from two donors. 695 The effect of spacer length on the knock-down activity by 697 PspCas13b. a) The effect of spacer length on antiviral activity of mCh3 crRNA 698 against DENV2-mCherry and DENV2-mAmetrine. The right panel shows the tiled 699 spacer sequences of mCh3 crRNAs. The right plot display the knock-down level of 700 each DENV2 reporter with mCh3 crRNA of different spacer length. b) crRNAs with 701 22-nucleotide spacer could enhance the accessibility of a target region on ZIKV 702 NS2A gene. c) Dose-response curve of Cas13b RNP delivered by VLP in BHK21 703 cells for three pairs of 22-nt vs. 30-nt crRNAs (mCh3, mAmet1, and 8681). d) The 704 enhancement effect by 22-nt spacer on the antiviral activity of the mCh3 crRNA was 705 observed in multiple cells such as 293T, BHK21, hDC, and iMHC. e) The 706 enhancement effect by 22-nt spacer of the mCh3 crRNA on knock down of 707 overexpressed mCherry reporter gene. The measurements were done in triplicate 708 for a) and duplicate for b)-e). Error bar = standard deviation. 709 Short spacer did not inhibit crRNA processing and multiplex 711 targeting of PspCas13b by a crRNA array. a) The sequences 30-nt and 22-nt 712 crRNA arrays used for testing in vitro crRNA processing and multiplex targeting. DR 713 = direct repeat. b) In vitro crRNA processing analyzed by 8M urea PAGE. 3x = 714",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "the site of 76 flaviviral RNA replication is associated with ER membrane(Neufeldt et al., 2018), localizing PspCas13b to ER with tail-anchor sequences such as SQS or 78 VAMP2(Guna et al., 2018) failed to suppress DENV2-mCherry infection 79",
            "latex": null,
            "type": "table"
        },
        "TABREF1": {
            "text": "). Thus, PspCas13b with 8681 crRNA could retard DENV2 infection and 96 protect host cell from its cytopathic effect in the absence of functional host antiviral 97 Despite a relatively high and stable expression of CRISPR-Cas13b in our setup (an 100 estimate of 994 ng/100,000 cells when induced with doxycycline at 0.1\u00b5g/ml), 101 delivery needs to be improved for practical use. Lentivirus delivery of CRISPR-102 Cas13 expression cassettes into cells has several limitations. It requires 103 transcription and translation of CRISPR-Cas13 before the effector becomes 104 available to target viral RNA, a process which require several hours and could affect 105 the effectiveness of virus suppression. CRISPR-Cas13 could also be permanently 106 engrafted into the host genome, a process that carries risks of transforming host 107 cells and Cas13-toxicity from prolonged expression. Recently, retrovirus has been 108 re-engineered to deliver protein cargoes and Cas9-gRNA ribonucleoprotein (RNP) 109 into cells in the form of virus-like particle (VLP)(Kaczmarczyk et al., 2011; Mangeot avoids genotoxicity. To produce VLP for Cas13b RNP delivery, we fused 112 PspCas13b gene to GAG gene to construct GAG-PspCas13b plasmid and co-113 transfected it with crRNA, Gag-Pol, and VSV-G plasmids into 293T (Supplementary 114 Figure 2a). We first tested VLP delivery of yellow fluorescent protein (YFP) into 115 various dengue natural target cells that include human primary cells such as human 116 dendritic cells (hDC), macrophages, CD14 + monocytes(Durbin et al., 2008; Jessie et 117 al., 2004), and hepatocytes(Aye et al., 2014) (iMHC",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}